Abivax SA Sponsored ADR (NASDAQ:ABVX – Get Free Report) was the recipient of a significant decline in short interest during the month of October. As of October 30th, there was short interest totaling 4,110,784 shares, a decline of 43.3% from the October 15th total of 7,254,941 shares. Currently, 4.7% of the company’s stock are sold short. Based on an average trading volume of 888,647 shares, the days-to-cover ratio is presently 4.6 days.
Abivax Price Performance
NASDAQ:ABVX traded up $1.68 during midday trading on Wednesday, reaching $83.78. The stock had a trading volume of 214,514 shares, compared to its average volume of 1,363,786. Abivax has a 1-year low of $69.81 and a 1-year high of $148.83. The firm’s fifty day simple moving average is $93.49 and its 200-day simple moving average is $112.22. The stock has a market capitalization of $7.33 billion, a P/E ratio of -13.84 and a beta of 1.36.
Abivax (NASDAQ:ABVX – Get Free Report) last announced its earnings results on Monday, September 21st. The company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.79). The company had revenue of $1.37 million for the quarter, compared to analysts’ expectations of $0.80 million. On average, equities research analysts anticipate that Abivax will post -4.14 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on ABVX shares. Truist Financial cut their price target on shares of Abivax from $155.00 to $151.00 and set a “buy” rating on the stock in a report on Tuesday, September 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a report on Thursday, October 15th. Barclays reissued an “overweight” rating and set a $148.00 target price on shares of Abivax in a research report on Tuesday, September 22nd. Wedbush reduced their price target on Abivax from $118.00 to $96.00 and set a “neutral” rating for the company in a research report on Wednesday, October 21st. Finally, Wall Street Zen downgraded Abivax from a “hold” rating to a “sell” rating in a research note on Saturday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $155.00.
Get Our Latest Research Report on Abivax
Institutional Investors Weigh In On Abivax
Hedge funds and other institutional investors have recently made changes to their positions in the business. Integrated Wealth Concepts LLC grew its stake in shares of Abivax by 16.7% in the third quarter. Integrated Wealth Concepts LLC now owns 2,908 shares of the company’s stock worth $288,000 after acquiring an additional 416 shares during the last quarter. Diversify Wealth Management LLC raised its stake in Abivax by 19.0% during the 3rd quarter. Diversify Wealth Management LLC now owns 24,780 shares of the company’s stock valued at $2,289,000 after purchasing an additional 3,963 shares during the last quarter. Diversify Advisory Services LLC raised its stake in Abivax by 19.0% during the 3rd quarter. Diversify Advisory Services LLC now owns 24,780 shares of the company’s stock valued at $2,289,000 after purchasing an additional 3,963 shares during the last quarter. Findell Capital Management LLC bought a new stake in Abivax in the 3rd quarter valued at $16,833,000. Finally, Integral Health Asset Management LLC bought a new stake in Abivax in the 3rd quarter valued at $4,951,000. 47.91% of the stock is owned by institutional investors and hedge funds.
Abivax Company Profile
Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response. The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally.
Further Reading
- Five stocks we like better than Abivax
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
